Diffuse Large B-cell Lymphoma: Clinical Trials

15 trials for Diffuse Large B-cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed. 15 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 315Completed 15
Phase 22Completed 2

Follow Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Diffuse Large B-cell Lymphoma trials Research Report on Diffuse Large B-cell Lymphoma

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL
R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone), Tucidinostat, Placebo - Diffuse Large B-cell Lymphoma
Phase 3CompletedChipscreen Biosciences, Ltd.4232020-05-212026-04-08
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Polatuzumab Vedotin, Rituximab, Gemcitabine - Diffuse Large B-Cell Lymphoma
Phase 3CompletedHoffmann-La Roche2702020-02-072025-12-22
A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL
SIBP-02, Rituximab - Diffuse Large B-Cell Lymphoma
Phase 3CompletedShanghai Institute Of Biological Products4212019-07-252023-12-27
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Enzastaurin Hydrochloride, R-CHOP + placebo - Diffuse Large B-Cell Lymphoma
Phase 3CompletedDenovo Biopharma LLC2562018-03-202025-01-23
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma
Phase 3CompletedHoffmann-La Roche10002017-11-162026-05-08
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Rituximab (RTX), Tafasitamab, Bendamustine (BEN) - Diffuse Large B-cell Lymphoma
Phase 2 / Phase 3CompletedIncyte Corporation4532016-11-282025-07-17
MabionCD20 Compared to MabThera in Lymphoma Patients
Rituximab, Doxorubicin, Vincristine - Diffuse Large B-Cell Lymphoma
Phase 3CompletedMabion SA1432015-12-012023-10-25
Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma
RTXM83, Mabthera - Diffuse Large B-cell Lymphoma
Phase 3CompletedmAbxience Research S.L.2722013-05-012019-09-26
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Pixantrone + Rituximab, Gemcitabine + Rituximab - Diffuse Large B-cell Lymphoma, de Novo DLBCL
Phase 3CompletedCTI BioPharma3122011-04-202021-11-19
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 3CompletedFred Hutchinson Cancer Center1742010-11-012026-04-30
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Lenalidomide, Gemcitabine, Oxaliplatin - Diffuse Large B-cell Lymphoma
Phase 2 / Phase 3CompletedCelgene1112010-09-022019-11-25
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Everolimus, Everolimus Placebo - Diffuse Large B-cell Lymphoma
Phase 3CompletedNovartis Pharmaceuticals7422009-07-242017-07-12
Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP
Lenalidomide, Placebo - Lymphoma, Diffuse Large B-cell Lymphoma
Phase 3CompletedThe Lymphoma Academic Research Organisation6502009-04-012021-07-26
Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.
Rituximab-HDS, Rituximab-CHOP - Diffuse Large B-Cell Lymphoma
Phase 3CompletedGruppo Italiano Terapie Innovative nei Linfomi2462005-05-012017-08-10
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Total-Body Irradiation, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Phase 3CompletedFred Hutchinson Cancer Center872003-10-012017-05-15

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (15)  ·  Lymphoma (4)  ·  Lymphoma, Non-Hodgkin (4)  ·  Hematologic Neoplasms (3)  ·  Hodgkin Disease (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lymphoma, Mantle-Cell (2)  ·  Multiple Myeloma (2)  ·  Recurrence (2)  ·  Waldenstrom Macroglobulinemia (2)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Leukemia, Myeloid, Chronic-Phase (1)  ·  Leukemia, Prolymphocytic (1)  ·  Leukemia, Prolymphocytic, T-Cell (1)

Broader conditions

Hemic and Lymphatic Diseases (15)  ·  Immune System Diseases (15)  ·  Immunoproliferative Disorders (15)  ·  Lymphatic Diseases (15)  ·  Lymphoproliferative Disorders (15)  ·  Neoplasms (15)  ·  Neoplasms by Histologic Type (15)  ·  Lymphoma, B-Cell (14)  ·  Lymphoma (11)  ·  Lymphoma, Non-Hodgkin (11)  ·  Disease Attributes (4)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Hematologic Diseases (3)  ·  Neoplasms by Site (3)

Interventions

Rituximab (9)  ·  Cyclophosphamide (3)  ·  Doxorubicin (3)  ·  Gemcitabine (3)  ·  Prednisone (3)  ·  Vincristine (3)  ·  Cyclosporine (2)  ·  Cyclosporins (2)  ·  Lenalidomide (2)  ·  Mycophenolic Acid (2)  ·  Oxaliplatin (2)  ·  Peripheral Blood Stem Cell Transplantation (2)  ·  Whole-Body Irradiation (2)  ·  fludarabine phosphate (2)  ·  polatuzumab vedotin (2)

Sponsors

Fred Hutchinson Cancer Center (2)  ·  Hoffmann-La Roche (2)  ·  CTI BioPharma (1)  ·  Celgene (1)  ·  Chipscreen Biosciences, Ltd. (1)  ·  Denovo Biopharma LLC (1)  ·  Gruppo Italiano Terapie Innovative nei Linfomi (1)  ·  Incyte Corporation (1)  ·  Mabion SA (1)  ·  Novartis Pharmaceuticals (1)  ·  Shanghai Institute Of Biological Products (1)  ·  The Lymphoma Academic Research Organisation (1)  ·  mAbxience Research S.L. (1)

Countries

United States (9)  ·  Italy (8)  ·  France (7)  ·  Germany (7)  ·  Spain (7)  ·  Austria (6)  ·  China (6)  ·  Poland (6)  ·  Australia (5)  ·  Czechia (5)  ·  United Kingdom (5)  ·  Brazil (4)  ·  Canada (4)  ·  Russia (4)  ·  South Korea (4)

Top investigators

Brenda Sandmaier (2)  ·  Adrian Kilcoyne, MD (1)  ·  Jun Zhu, Professor (1)  ·  Sergio Cortelazzo, MD (1)  ·  Simran B Singh, MS, GWCP (1)  ·  Weili Zhao, Professor (1)

Results publications

PMID 32499241, PMID 21495023, PMID 27093976, PMID 28381416, PMID 29253068, PMID 31248843, PMID 31879945, PMID 31978225, PMID 32250167, PMID 32817282, PMID 33278600, PMID 34904799, PMID 35710733, PMID 35726803, PMID 36626583, PMID 36740991, PMID 37864313, PMID 40085955, PMID 40991874, PMID 40997297, PMID 41056515, PMID 42018318, PMID 42407012, PMID 42699559

NIH funding

P30CA015704 (2), 2008 (1), 2014 (1), 2017 (1), 2018 (1), P01CA018029 (1), P01CA078902 (1)